Intercept Pharmaceuticals, striving to launch the world’s first treatment for a pervasive liver disease, spelled out its plans for a sizable Phase III study designed to secure an accelerated approval and help the company retain pole position in a potentially lucrative field.

…read more

Source: Intercept plots a big Phase III NASH trial with room for an early approval


0 No comments